1. Home
  2. GBIO vs NVNI Comparison

GBIO vs NVNI Comparison

Compare GBIO & NVNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GBIO
  • NVNI
  • Stock Information
  • Founded
  • GBIO 2016
  • NVNI 2019
  • Country
  • GBIO United States
  • NVNI Brazil
  • Employees
  • GBIO N/A
  • NVNI N/A
  • Industry
  • GBIO Biotechnology: Pharmaceutical Preparations
  • NVNI
  • Sector
  • GBIO Health Care
  • NVNI
  • Exchange
  • GBIO Nasdaq
  • NVNI Nasdaq
  • Market Cap
  • GBIO 29.2M
  • NVNI 31.5M
  • IPO Year
  • GBIO 2020
  • NVNI N/A
  • Fundamental
  • Price
  • GBIO $0.38
  • NVNI $0.34
  • Analyst Decision
  • GBIO Strong Buy
  • NVNI
  • Analyst Count
  • GBIO 4
  • NVNI 0
  • Target Price
  • GBIO $7.33
  • NVNI N/A
  • AVG Volume (30 Days)
  • GBIO 1.1M
  • NVNI 1.4M
  • Earning Date
  • GBIO 08-06-2025
  • NVNI 08-07-2025
  • Dividend Yield
  • GBIO N/A
  • NVNI N/A
  • EPS Growth
  • GBIO N/A
  • NVNI N/A
  • EPS
  • GBIO N/A
  • NVNI N/A
  • Revenue
  • GBIO $24,556,000.00
  • NVNI $31,250,627.00
  • Revenue This Year
  • GBIO N/A
  • NVNI $12.05
  • Revenue Next Year
  • GBIO N/A
  • NVNI $15.02
  • P/E Ratio
  • GBIO N/A
  • NVNI N/A
  • Revenue Growth
  • GBIO 146.47
  • NVNI 1491.58
  • 52 Week Low
  • GBIO $0.30
  • NVNI $0.14
  • 52 Week High
  • GBIO $3.65
  • NVNI $12.19
  • Technical
  • Relative Strength Index (RSI)
  • GBIO 49.21
  • NVNI 51.35
  • Support Level
  • GBIO $0.32
  • NVNI $0.28
  • Resistance Level
  • GBIO $0.36
  • NVNI $0.38
  • Average True Range (ATR)
  • GBIO 0.03
  • NVNI 0.03
  • MACD
  • GBIO 0.00
  • NVNI 0.01
  • Stochastic Oscillator
  • GBIO 64.67
  • NVNI 64.11

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

Share on Social Networks: